Amyris Q2 2016 Earnings Call August 4

Amyris reported Q2 2016 earnings with non-GAAP revenue of $12.4M (138% growth) and GAAP revenue of $9.6M (23% growth), along with a 21% reduction in SG&A expenses. The company outlined 2016 targets including adjusted operating expenses of $70-75M and expected collaboration inflows of $18-20M in Q3, while advancing partnerships with Ginkgo Bioworks and Biogen in the biopharmaceutical sector.